IRUBIS

IRUBIS GmbH, a Munich-based company, was founded in 2017 by Anja Müller, Alexander Geißler, and Lorenz Sykora-Mirle. The company operates in the biotechnology sector, specializing in Process Analytical Technology (PAT) for the biopharmaceutical industry.

IRUBIS has developed Monipa, a solution based on mid-infrared (MIR) spectroscopy for real-time monitoring and control of bioprocesses. This technology allows for the simultaneous measurement of multiple critical process parameters, such as the concentration of nutrients, metabolites, and product titers. Monipa is designed to be used inline or online, providing continuous data streams that enable better process understanding and control, leading to improved yield, quality, and consistency of biological drugs.

The system is particularly aimed at companies involved in the development and manufacturing of biologics, including monoclonal antibodies, vaccines, and cell and gene therapies. By providing real-time insights into the bioprocess, Monipa helps to accelerate process development, reduce the number of failed batches, and ultimately bring new drugs to market faster. The business model likely revolves around the sale of the Monipa instrument, consumables such as single-use flow cells, and potentially software and support services.

Keywords: mid-infrared spectroscopy, bioprocessing, process analytical technology, biopharmaceutical manufacturing, real-time monitoring, biologics, monoclonal antibodies, cell therapy, gene therapy, process control